Abstract
The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 941-945 |
| Number of pages | 5 |
| Journal | Acta Oncologica |
| Volume | 30 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1 Jan 1991 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- B-2 microglobulin
- Renal cell carcinoma
- Survival
ASJC Scopus subject areas
- Hematology
- Oncology
- Radiology Nuclear Medicine and imaging
Fingerprint
Dive into the research topics of 'Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver